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PHARMACOECONOMIC CLAIMS IN PRESCRIPTION DRUG
ADVERTISEMENTS IN FINNISH MEDICAL JOURNALS
Norjamäki A1, Martikainen J2,Turunen J2, Kivioja A1
1Ministry of Social Affairs and Health, Helsinki, Finland; 2University of
Kuopio, Kuopio, Finland
OBJECTIVES: To determine the number of pharmacoeconomic
messages in prescription drug advertisements in major Finnish
medical journals and whether their number has increased over
time. Additionally, to determine what kinds of claims these
advertisements include, whether supporting evidence is provided,
whether generic substitution has had an effect on the number
and which drugs were most frequently promoted. METHODS:
Prescription drug advertisements in three Finnish medical jour-
nals were examined. The ﬁrst issue published in January, July
and October in 1990–2003 was examined. All prescription drug
advertisements in the journals were counted and the ones with
economic messages were copied and analyzed with a structured
data collection form. RESULTS: There were 2175 advertise-
ments in the sample of 126 journals, of which 455 included 
economic and 294 quality of life—messages. The number of eco-
nomic content ads had increased from 19 in 1990 to 54 in 2003
(Pearson 0.75). The most frequently used economic claims were
cheap or economical and references to reimbursement or price.
The most often used quality of life claims were quality of life,
easy, good or better life or day or statements describing life (e.g.
balanced). Evidence for economic claims was found in 23% of
the advertisements and more than half of them referred to the
price list. Evidence for quality of life claims was found in 20%
of the ads and most of them referred to scientiﬁc studies. Generic
drugs were advertised most in 2001–2002, just before the generic
substitution was initiated in Finland. Economic messages were
most frequently used for antidepressants, ACE inhibitors and
anti-inﬂammatory drugs. CONCLUSIONS: 1) The number of
economic content advertisements has increased over time in
Finnish medical journals. 2) Evidence for the claims was found
in approximately 20% of the advertisements.
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BELIEFS ABOUT MEDICINES AMONG SWEDISH PHARMACY
EMPLOYEES
Jörgensen T,Andersson K, Mårdby AC
Göteborg University, Göteborg, Sweden
OBJECTIVES: Health professionals hold both professional and
personal health beliefs, and it is likely that this has an impact on
both which information one communicates and how. The impor-
tance of beliefs in relation to adherence to treatment has been
stressed, but is not yet fully appreciated by health professionals.
A larger project will analyse and compare beliefs about medi-
cines among health professionals and patients. The aim of this
study was to describe beliefs about medicines among pharmacy
employees. METHODS: The study was performed among phar-
macy employees at 24 community pharmacies in Göteborg,
Sweden. The participating pharmacies had a total of 372
employees (pharmacists, dispensing pharmacists, pharmacy tech-
nicians). Data collection was at the weekly pharmacy informa-
tion meetings with a questionnaire comprising background
questions (age, professional category, working experience and
medication use) and the general part of Beliefs about Medicines
Questionnaire (BMQ). RESULTS: A majority of the 292 respon-
dents were dispensing pharmacists. More than half of the respon-
dents were aged 45 years or older and had worked in a pharmacy
for 20 years or more. A higher proportion of dispensing phar-
macists stated current use of traditional medicines compared to
the other professional categories. The respondents had a high
mean value for General Beneﬁt and a low mean value for General
Harm. Compared to dispensing pharmacists, pharmacy techni-
cians viewed medicines as more harmful (p = 0.001); and com-
pared to pharmacy technicians, dispensing pharmacists regarded
medicines as more beneﬁcial (p = 0.001). When controlling for
background characteristics, no confounders were detected for
any of the three subscales. CONCLUSIONS: The reason for the
difference between dispensing pharmacists and technicians
remain unclear. Nevertheless, the positive beliefs among phar-
macy personnel may have an impact on the communication with
clients and, eventually, adherence.
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PUBLIC FUNDING OF DRUGS FOR ORPHAN DISEASES
Hughes D
University of Wales, Bangor, Gwynedd, UK
The EU regulation on orphan medicinal products aims to
promote the research and development of treatments for rare 
diseases. Approval by licensing authorities, however, does not
necessitate that health services reimburse such treatments.
OBJECTIVES: To assess whether cost-effectiveness analysis, as
conventionally applied, is appropriate for orphan drugs by con-
sidering whether availability of patients in the case of “ultra-
orphan” drugs is sufﬁcient for adequate statistical powering.
METHODS: Simulations of sample size for cost-effectiveness
analysis, based on Briggs & Tambour (1998) using the net-
beneﬁt approach, were conducted. Different values for costs and
beneﬁts (QALYs) for treatment and control groups, together
with their respective variances and co-variances were imputed.
For different values of threshold willingness to pay per additional
QALY, the relationship between sample size and statistical power
were determined. RESULTS: For a willingness to pay threshold
of £30,000 per additional QALY, a difference in costs DC =
£20,000, difference in beneﬁt DB = 1 QALY, variance in treat-
ment and control beneﬁt s2(B) = 10 QALYs, variance in treat-
ment and control cost s2(C) = £106 and covariance of DC and
DB set as zero, statistical power ranged from 8% for sample sizes
of 50 per arm to 65% for sample sizes of 1000 per arm. CON-
CLUSIONS: Certain diseases are sufﬁciently rare that even if 
all patients were included in a clinical trial, adequate statisti-
cal power for cost-effectiveness of treatments may never be
achieved. Further, trials for orphan drugs are often non-
comparative which also detracts from the reliance that may be
placed on inferences on clinical and /or cost-effectiveness. For
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rare diseases, consideration of alternative acceptance criteria for
public reimbursement /health service provision may be required.
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THE IMPACT ON DECISION-MAKING OF CHANGING COST-
EFFECTIVENESS OF HEALTH TECHNOLOGIES OVER TIME
Pang F1,Tolley K2
1Abbott Laboratories Ltd, Maidenhead, Berkshire, UK; 2MAPI VALUES,
Bollington, UK
OBJECTIVES: Estimation of cost-effectiveness of health tech-
nologies tends to focus on the time period at or around launch,
to fulﬁll the growing requirements of reimbursement or market
access agencies. This study reviews the factors which inﬂuence
cost-effectiveness over time and demonstrates the temporal
impact on cost-effectiveness using a number of case-studies. The
implications for decision making and market access are dis-
cussed. METHODS: A review of the factors that may inﬂuence
cost-effectiveness over time and methodological approaches used
to address these was conducted. Earlier analytical frameworks
of studies from the 1990s in the ﬁelds of motor airbags,
implantable cardiac deﬁbrillators, statins, renal dialysis and
hearing aids were revisited to re-estimate the cost-effectiveness.
For example, parameters of an economic evaluation conducted
in 1990 for erythropoetin were updated to 2004 values using a
recent systematic review of clinical evidence together with
revised unit costs and expert clinical opinion for resource utili-
sation. RESULTS: For the majority of case-studies examined,
there was a trend for the reduction in cost-effectiveness ratios
over time—e.g. for erythropoetin, the base-case cost per QALY
decreased ten-fold over a 14 year period (£216,906 to £21,547).
Signiﬁcant factors included unit costs, dosage, utility gains 
and revised discounted rates. CONCLUSIONS: The timing of
economic evaluation is critical in the estimation of cost-
effectiveness. Production of this evidence may often be the ﬁrst
time that the conceptual framework of economic analysis has
been applied to the technology, despite suggestions that eco-
nomic evaluation should be used iteratively throughout the
product life-cycle. This study has demonstrated that whilst 
there is a need for economic evaluation results to be timely to
aid decision-making (i.e. at or around launch), it is important
that the analysis is updated and reviewed periodically to assess
whether cost-effectiveness has changed sufﬁciently to justify
modifying the original decision.
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EXAMINING THE QUALITY OF HEALTH ECONOMIC
ANALYSES SUBMITTED TO THE REIMBURSEMENT AGENCIES
IN SWEDEN AND FINLAND—A CROSS COUNTRY
COMPARISON
Engstrom A1, Kivioja A2
1Pharmaceutical Beneﬁts Board, Solna, Sweden; 2Ministry of Social
Affairs and Health, Helsinki, Finland
OBJECTIVES: To compare the quality of the health economic
material submitted to the Swedish Pharmaceutical Beneﬁts Board
and the Finnish Pharmaceuticals Pricing Board as part of 
the application for reimbursement for new pharmaceuticals.
METHODS: The health economic evaluations were reviewed in
each country against two checklists, marking each question
Yes/No/Not Applicable. The checklists used were: 1) the respec-
tive national Guidelines transformed into yes or no questions,
and 2) the QHES check list, a validated instrument, was also
used to provide a common comparator. The central estimate of
cost effectiveness was collected (cost per QALY) as well as
whether the application was accepted or rejected in each country.
RESULTS: The Swedish scores range from 0.24 to 0.87 and on
the QHES from 0.09 to 1, with a mean quality of 0.61 and 0.67
respectively. The Finnish scores range from 0.58 to 0.96 and on
the QHES from 0.28 to 0.84, with a mean quality of 0.76 and
0.62 respectively. The correlation between the respective national
guidelines and the QHES scores is modest (approx. 0.7 both in
Sweden and in Finland). This is mostly due to country speciﬁc
criteria. There was a low observed correlation between quality
score and acceptance in Sweden and also in Finland. Likewise,
the correlation between cost per QALY and decision to
accept/reject is low to medium. CONCLUSIONS: Health eco-
nomic material as part of applications to reimbursement agen-
cies varies widely in quality. There are differences even for the
same product in the two countries. Secondly, due to the relatively
small number of applications studied and the even fewer rejec-
tions, it is difﬁcult to draw ﬁrm conclusions regarding the value
the pricing authorities studied place on a QALY.
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PAYMENT FOR PHARMACY HANDLING COSTS IN THE HOPD:
2006 REIMBURSEMENT IMPLICATIONS
Baker JJ1, Panarites CJ2
1The Resource Group, Dallas,TX, USA; 2Scios, Inc, Fremont, CA, USA
OBJECTIVE: Medicare reform legislation requires the Medicare
Payment Advisory Commission (MedPAC) to conduct a study of
hospital pharmacy handling costs and to recommend whether
payment for handling costs of Part B speciﬁed outpatient drugs
should be made under the Medicare Hospital Outpatient
Prospective Payment System (OPPS). This study explores the
MedPAC approach to pharmacy departmental costs and poten-
tial reimbursement implications. METHODS: The MedPAC
rationale and recommendations were deconstructed, evaluated,
and compared to data about pharmacy operations obtained from
two studies. The ﬁrst study collected data from on-site observa-
tions of infusion therapy and related pharmacy activities in 24
hospital outpatient departments (HOPDs) located in 19 states.
A subsequent telephone survey gathered information about
stafﬁng and workﬂow from 30 other hospital pharmacy direc-
tors located in 16 states and the District of Columbia. RESULTS:
The MedPAC report places pharmacy costs into ﬁve categories;
concludes that hospitals can estimate these costs; and recom-
mends that hospitals develop and submit charges for a new set
of handling fee APCs. Findings from the comparative on-site
observations and telephone survey, however, reveal that signiﬁ-
cant portions of certain costs are not charged to the pharmacy.
For example, 69.1% of respondents had information systems
costs charged outside the department while 34.5% reported their
entire information systems costs charged elsewhere. Likewise,
73.3% of respondents reported reimbursement, chargemaster,
clerical and transport staff utilized by the pharmacy department
but not charged to the department. Such disparities in depart-
mental costing will signiﬁcantly hinder the uniform interpreta-
tion of costs assumed by MedPAC. CONCLUSIONS: Payment
methods in 2006 for handling costs of Part B separately paid
drugs will be derived in large part from the MedPAC recom-
mendations. If the payment methodology does not take existing
variations in recording pharmacy expense outside the depart-
ment, hospital providers may well be underpaid for handling
costs in 2006.
PHP43
IMPACT OF PHARMACEUTICAL POLICIES ON
PROMOTIONAL TARGETED DRUGS
Layton MR1, Chadbunchachai S1,Thinkhamrop B1,
Tangcharoensathien V2,Wertheimer AI3
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